In terms of year-over-year revenue growth, Takeda observed a 5.87% increase, while JNJ and BMY had an 11.02% and 0.68% decrease respectively. On the other hand, ...

Takeda Pharmaceutical reports 4.6% YoY revenue growth in 3Q23, driven by positive forex moves and pipeline advancements. Click here for more on TAK stock.

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & ...

ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...

We recently compiled a list of the 10 Best Japanese Stocks To Buy Now. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the ...

Takeda reported a 25% drop in FY2024 net profit but saw revenue and operating profit growth. ... The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment. Vandana Singh. 40%. Financials.

Plasma collection has recently returned to pre-pandemic levels at Takeda, and the company expects about 10% to 20% donation volume growth year over year in its fiscal year that ends in March 2023.

Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024; Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings ...

The PDT business posted 9% growth in 2024. Takeda’s broad immunoglobulin ... The Zacks Consensus Estimate for ADMA’s 2025 sales implies a year-over-year increase of 18.61%, and that ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of ...